Effect of Gymnema montanum Leaves on Serum and Tissue Lipids in Alloxan Diabetic Rats by Ananthan, R. et al.
Experimental Diab. Res., 4:183–189, 2003
Copyright c  Taylor and Francis Inc.
ISSN: 1543-8600 print / 1543-8619 online
DOI: 10.1080/15438600390244353
Effect of Gymnema montanum Leaves on Serum and Tissue
Lipids in Alloxan Diabetic Rats
R. Ananthan,1 M. Latha,2 K. M. Ramkumar,2 L. Pari,2 C. Baskar,1
and V. Narmatha Bai1
1Department of Botany, Bharathiar University, Coimbatore, Tamil Nadu, India
2Department of Biochemistry, Faculty of Science, Annamalai University, Annamalainagar,
Tamil Nadu, India
The effect of Gymnema montanum leaves on alloxan-
induced hyperlipidemia was studied in male Wistar rats.
Ethanolic extract of G. montanum leaves was administered
orally and different doses of the extract on blood glucose,
serumandtissuelipids,hexokinase,glucose-6-phosphatase,
thiobarbituric acid–reactive substances (TBARS), hy-
droperoxides, and glutathione in alloxan-induced diabetic
ratswerestudied.G.montanumleafextract(GLEt)atdoses
of 50, 100, 200 mg/kg body weight for 3 weeks suppressed
the elevated blood glucose and lipid levels in diabetic rats.
GLEt at 200 mg/kg body weight was found to be compa-
rable to glibenclamide, a reference drug. These data indi-
cate that G. montanum represents an effective antihyper-
glycemic and antihyperlipidemic adjunct for the treatment
ofdiabetesandapotentialsourceofdiscoveryofneworally
active agent for future therapy.
Keywords Alloxan Diabetes; Blood Glucose; Carbohydrate
Enzymes; Gymnema montanum; Lipids
Experimental diabetes in animals has provided considerable
insight into the physiologic and biochemical derangements of
the diabetic state. Many of the derangements have been charac-
terized in hyperglycemic animals. Signiﬁcant changes in lipid
metabolism and structure also occur in diabetes [1]. In these
cases, the structural changes are clearly oxidative in nature and
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areassociatedwithdevelopmentofvasculardiseaseindiabetes
[2]. In diabetic rats, increased lipid peroxidation was also asso-
ciated with the hyperlipidemia [3]. Liver, an insulin-dependent
tissue that plays a pivotal role in glucose and lipid homeostasis,
isseverelyaffectedduringdiabetes[4].Liverparticipatesinthe
uptake, oxidation, and metabolic conversion of free fatty acids,
synthesis of cholesterol, phospholipids, and triglycerides. Dur-
ing diabetes, a profound alteration in the concentration and
composition of lipid occurs. Decreased glycolysis, impeded
glycogenesis, and increased glyconeogenesis are some of the
changes of glucose metabolism in the diabetic liver [5].
For various reasons, in recent years the popularity of com-
plementary medicine has increased. Dietary measures and tra-
ditional plant therapies as prescribed by ayurvedic and other
indigenous systems of medicine are used commonly in India
[6]. In recent times, many traditionally used medicinally im-
portant plants were tested for their antidiabetic potential by
various investigations in experimental animals [7].
Gymnema montanum Hook [8] belongs to the family As-
clepiadaceae; it is an endemic and endangered plant species of
IndiafoundmainlyinWesternghats[9].Exceptafewcommon
species, the majority of the species shows various levels of rar-
ity and G. montanum is one such species that have been taken
for our study.
Previously we have reported the effect of G. montanum on
rate-limiting enzymes of glycolysis and gluconeogenesis in
liverofdiabeticanimals[10].Thisstudywasthusinitiatedwith
the aim of evaluating the effects of ethanolic extract of G. mon-
tanum leaves on serum and tissue lipids in alloxan diabetic
rats.
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MATERIALS AND METHODS
Animals
Male albino Wistar rats, body weight of 180 to 200 g,
bred in Central Animal House, Rajah Muthiah Medical Col-
lege, Annamalai University, were used in this study. The an-
imals were fed on a pellet diet (Hindustan Lever, India) and
water ad libitum. The animals were maintained in a con-
trolled environment under standard conditions of temperature
and humidity with an alternating light and dark cycle. The
animals used in the present study were maintained in accor-
dance with the guidelines prescribed by the National Institute
of Nutrition, Indian Council of Medical Research, Hyderabad,
India, and approved by the Ethical Committee, Annamalai
University.
Plant Material
G. montanum leaves were collected freshly from the Shola
forests of Western Ghats, Gudalur, The Nilgiri Biosphere Re-
serve, at an altitude of 900 to 1500 m above sea level. The plant
was identiﬁed at the Herbarium of Botanical Survey of India,
Southern Circle, Coimbatore, India (accession no. 32561-65)
and was deposited in the Department of Botany, Bharathiar
University.
Preparation of Plant Extract
To prepare the G. montanum leaf extract (GLEt), 500 g of
fresh leaves of G. montanum were chopped into small pieces
and soaked overnight in 1.5 L of 95% ethanol. This suspension
wasﬁlteredandtheresiduewasresuspendedinanequalvolume
of95%ethanolfor48hoursandﬁlteredagain.Thetwoﬁltrates
were pooled and the solvents were evaporated in a rotavapor
at 40◦Ct o5 0 ◦C under reduced pressure and lyophilized. A
greenish-black powdered material was obtained (20 to 30 g). It
was stored at 0◦Ct o4 ◦C until used. When needed, the residual
extract was suspended in distilled water and administered by
oral intragastric tubes [11].
Experimental Induction of Diabetes
Rats were injected with freshly prepared solution of alloxan
monohydrate in normal saline by intraperitoneally at a dose of
150 mg/kg body weight [12]. Because alloxan is capable of
producing fatal hypoglycemia as a result of massive pancre-
atic insulin release, rats were treated with 20% glucose solu-
tion (5 to 10 mL) orally after 6 hours. The rats were then kept
for the next 24 hours on 5% glucose solution bottles in their
cages to prevent hypoglycemia [13]. After 3 weeks, rats with
moderate diabetes having glycosuria and hyperglycemia (i.e.,
with blood glucose of 200 to 300 mg/dL) were chosen for the
experiment.
Experimental Procedure
A total of 42 rats (30 diabetic surviving rats, 12 normal
rats) were used and they were divided into 7 groups of 6 rats
each.
Group 1: Normal untreated rats.
Group 2: Normal rats treated with GLEt (200 mg/kg body
weight [b.w.])
Group 3: Diabetic control.
Group 4: Diabetic rats treated with GLEt (50 mg/kg b.w.)
Group 5: Diabetic rats treated with GLEt (100 mg/kg b.w.)
Group 6: Diabetic rats treated with GLEt (200 mg/kg b.w.)
Group 7: Diabetic rats treated with glibenclamide (600 µg/kg
b.w.) [14].
TheGLEtandthereferencedrugglibenclamidewereadmin-
isteredbyoralintragastrictubesduringtheexperimentalperiod.
Body weights and food and ﬂuid intake of the experimental an-
imals were recorded at regular intervals. Food intake was de-
termined by measuring the difference between the preweighed
standard food and weight of the balanced and spilled food for
every 24 hours. Similarly the ﬂuid intake was measured by
monitoring the amount of ﬂuid given and the balanced ﬂuid.
At the end of 3 weeks, the animals were deprived of food
overnightandsacriﬁcedbydecapitation.Bloodwastakenfrom
the jugular vein and collected in 2 tubes: one with potassium
oxalate and sodium ﬂuoride solution for plasma and another
without anticoagulant for serum separation. The liver was im-
mediately dissected out, washed in ice-cold saline, patted dry,
and weighed.
Analytical Methods
Blood glucose was determined by the o-toluidine method
[15]. Plasma insulin was assayed by enzyme-linked im-
munosorbent assay (ELISA) method, using Boeheringer-
MannheimKitwithaBoeheringeranalyzerES300usinghuman
insulin as standard [16].
Lipids were extracted from serum and tissues by the method
ofFolchandcolleagues[17].Totalcholesterolandtriglycerides
were estimated by the method of Zlatkis and colleagues [18]
and Foster and Dunn [19], respectively. Free fatty acids and
phospholipids were analysed by the method of Falholt and col-
leagues [20] and Zilversmit and Davis [21]. The extent of lipid
peroxidation was estimated colorimetrically by thiobarbituricANTIHYPERLIPIDEMIC EFFECT OF GYMNEMA MONTANUM 185
acid–reactive substances (TBARS) and hydroperoxides by the
method of Nichans and Samuelson [22] and Jiang and col-
leagues [23], respectively. Reduced glutathione (GSH) was
determined by the method of Ellman [24]. Hexokinase (E.C
2.7.1.1) and glucose-6-phosphatase (E.C 3.1.3.9) were assayed
according to the method of Brandstrup and colleagues [25] and
Koida and Oda [26], respectively.
Statistical Analysis
All the data were expressed as mean ± SD of num-
ber of experiments (n = 6). The statistical signiﬁcance was
evaluated by one-way analysis of variance (ANOVA) using
SPSS version 7.5 (SPSS, Cary, NC, USA) and the individual
comparisons were obtained by Duncan’s multiple range test
(DMRT) [27].
RESULTS
The results of the present investigation are depicted in
Figure 1 and Tables 1 to 4. The treatment with ethanolic extract
ofG.montanumleavesreversedtheweightlossindiabeticrats.
FIGURE 1
Body weights (g) of control and experimental rats (mean ± SD; n = 6). Group 1, normal untreated rats; group 2, normal rats
given GLEt (200 mg kg−1 b.w.); group 3, diabetic control; group 4, diabetic rats given GLEt (50 mg kg−1 b.w.); group 5, diabetic
rats given GLEt (100 mg kg−1 b.w.); group 6, diabetic rats given GLEt (200 mg kg−1 b.w.); group 7, diabetic rats given
glibenclamide (600 mg kg−1 b.w.). Measurements were taken weekly until the experimental period. b.w. = body weight.
The body weight changes of the experimental animals are
presented in Figure 1. At the end of the experimental period,
the body weights of the diabetic animals were signiﬁcantly re-
duced when compare to normal animals. The body weights
in the GLEt-treated and glibenclamide-treated groups were in-
creasedsigniﬁcantly(P <.001)attheendofthe3rdweekwhen
compared with the diabetic control group.
Table 1 represents the changes in the water and food intake
in normal and experimental diabetic rats. The food and wa-
ter intake signiﬁcantly increased in diabetic control rats and it
was signiﬁcantly reduced in GLEt- and glibenclamide-treated
groups than diabetic control rats.
In all groups prior to alloxan administration, the basal lev-
els of blood glucose of the rats were not signiﬁcantly differ-
ent. However, 15 days after alloxan administration, blood glu-
cose levels were signiﬁcantly higher in the experimental rats
selected for the study. Table 2 shows the effect of GLEt and
glibenclamide on blood glucose levels. Although a signiﬁcant
antihyperglycemic effect was evident from the 1st week on-
wards, the decrease in blood glucose was maximum on 3rd
week, with signiﬁcant increase in plasma insulin in group re-
ceiving 200 mg/kg body weight of GLEt. The effect of GLEt at186 R. ANANTHAN ET AL.
TABLE 1
Changes in food intake and ﬂuid intake in normal and experimental rats
Fluid intake (mL/rat per day) Food intake (g/rat per day)
Groups Before After Before After
Normal 75 ± 8.12 73 ± 10a 15 ± 0.8 14 ± 0.9a
Normal + GLEt (200 mg/kg) 80 ± 6.07 77 ± 3a 18 ± 0.9 16 ± 0.8a
Diabetic control 155 ± 17.0 165 ± 30b 40 ± 3.0 56 ± 7.0b
Diabetic + GLEt (50 mg/kg) 135 ± 12.0 100 ± 15c 35 ± 5.0 48 ± 9.3c
Diabetic + GLEt (100 mg/kg) 128 ± 10.3 95 ± 9d 32 ± 6.2 40 ± 6.5d
Diabetic + GLEt (200 mg/kg) 120 ± 9.85 80 ± 7e 25 ± 2.0 30 ± 1.2e
Diabetic + glibenclamide 126 ± 22.0 92 ± 18 f 25 ± 1.5 32 ± 2.0e
Note. Values are given as mean ± SD from 6 rats in each group.
Values not sharing a common superscript letter differ signiﬁcantly at P <. 05 (DMRT), Duncan procedure;
range for the levels 2.95, 3.09, 3.20.
Superscripts denote signiﬁcance.
a dose of 200 mg/kg body weight was signiﬁcant as compared
to 50 and 100 mg/kg body weight and therefore the higher dose
was used for further biochemical studies. Normal rats treated
with 200 mg/kg body weight of GLEt also showed a decrease
in blood glucose level.
The effect of GLEt on serum and tissue lipids of normal and
experimental rats is summarized in Table 3. A marked increase
in the frequency of cholesterol, free fatty acids, triglycerides,
andphospholipidswereobservedindiabeticcontrolrats.Treat-
ment with GLEt signiﬁcantly reduced the lipid levels.
TABLE 2
Changes in blood glucose and plasma insulin of normal and experimental animals
Blood glucose (mg/dL)
15 days after 1 week 2 weeks 3 weeks
Groups Day 0 alloxan injection after treatment after treatment after treatment
Plasma insulin
(µU/mL)
after 3 weeks
Normal 79 ± 3.03 84 ± 5.14 82 ± 5.92 80 ± 6.04 81 ± 5.98 13.62 ± 5.52a
Normal + GLEt 84 ± 5.59 83 ± 4.66 81 ± 5.56 79 ± 4.30 75 ± 4.99 15.13 ± 0.90b
(200 mg/kg)
Diabetic control 81 ± 4.94 265 ± 19.45∗∗ 279 ± 12.93∗∗ 285 ± 12.95∗∗ 298 ± 15.77∗∗ 5.50 ± 2.75c
Diabetic + GLEt 83 ± 6.59 248 ± 14.02 215 ± 13.04∗ 180 ± 9.83∗∗ 161 ± 13.25∗∗ 9.16 ± 0.62d
(100 mg/kg)
Diabetic + GLEt 79 ± 5.09 258 ± 18.61 200 ± 12.58∗∗ 120 ± 6.39∗∗ 86 ± 9.25∗∗ 21.06 ± 4.32e
(200 mg/kg)
Diabetic + glibenclamide 77 ± 4.48 245 ± 13.99 219 ± 7.05∗ 191 ± 10.8∗∗ 118 ± 4.48∗∗ 10.08 ± 3.13 f
(600 µg/kg)
Note. Values are given as mean ± SD for 6 rats in each group.
Diabetic control was compared with normal. Experimental groups were compared with corresponding values after alloxan injection (15 days).
∗P <. 01, ∗∗P <. 001.
Values not sharing a common superscript letter differ signiﬁcantly at P <. 05 (DMRT), Duncan procedure; range for the levels 2.89, 3.03,
3.13, 3.20, 3.25.
Theextentoflipidperoxidation,glutathionecontent,andthe
activities of carbohydrate enzymes are represented in Table 4.
TBARS, hydroperoxides, and glucose-6-phosphatase activity
were signiﬁcantly increased, whereas glutathione and hexo-
kinase activities were signiﬁcantly decreased in liver of dia-
betic rats. Treatment with GLEt signiﬁcantly increased the glu-
tathionelevelandhexokinaseactivitiesandreducedthelevelof
TBARS, hydroperoxides, and glucose-6-phosphatase activity.
Normal rats treated with GLEt showed signiﬁcant changes in
tissue lipids.T
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TABLE 4
Change in the levels of liver TBARS, hydroperoxides, glutathione, hexokinase, and glucose-6-phosphatase in normal and
experimental animals
TBARS Hydroperoxides Glutathione Hexokinase Glucose-6-phosphatase
Groups (mM/100 g tissue) (mM/100 g tissue) (mg/100 mg tissue) (units∗/g protein) (units∗∗/mg protein)
Normal 0.76 ± 0.02a 75 ± 3.96a 46 ± 3.9a 142 ± 4.89a 0.162 ± 0.01a
Normal + GLEt 0.69 ± 0.02b 68 ± 2.12b 53 ± 2.02b 151 ± 3.07b 0.158 ± 0.01a
(200 mg/kg)
Diabetic control 1.72 ± 0.10c 93 ± 7.66c 23 ± 1.86c 109 ± 4.71c 0.272 ± 0.021b
Diabetic + GLEt 1.23 ± 0.03d 78 ± 5.58d 40 ± 2.88d 139 ± 8.09d 0.171 ± 0.024a,c
(200 mg/kg)
Diabetic + glibenclamide 1.30 ± 0.04e 81 ± 4.52d 34 ± 2.91e 137 ± 9.40d 0.182 ± 0.020c
(600 µg/kg)
Note. Values are given as mean ± SD for 6 rats in each group.
Valuesnotsharingacommonsuperscriptletterdiffersigniﬁcantlyat P <.05(DMRT),Duncanprocedure;rangeforthelevels2.95,3.09,3.20.
∗µmoles of glucose phosphorylated/min.
∗∗µmoles of Pi liberated/min.
DISCUSSION AND CONCLUSION
Hyperlipidemia is a metabolic complication of both clinical
and experimental diabetes [28]. In animals, the administration
of diabetogenic doses of alloxan induces hyperlipidemia [29].
In our present study, we have observed that an ethanolic extract
of GLEt can reverse the effects. The possible mechanism by
which GLEt brings about its antihyperglycemic action may
be by potentiation of pancreatic secretion of insulin from beta
cells of islets or due to enhanced transport of blood glucose to
peripheral tissue. This was clearly evidenced by the increased
levels of insulin in diabetic rats treated with GLEt. In this
context, a number of other plants have also been reported to
have antihyperglycemic and insulin-release stimulatory effect
[30, 31].
Excess free fatty acids in serum produced by the alloxan
lowerstheinsulin-mediatedglucosedisposalandpromotescon-
version of excess fatty acids into phospholipids and cholesterol
in liver. These two substances along with excess triglycerides
formed at the same time in the liver may be discharged into the
blood in the form of lipoprotein [32]. Both increased hepatic
production of triglycerides and decreased peripheral removal
havebeendemonstrated.Hypercholesteremiaandhypertriglyc-
eridemia have been reported to occur in diabetic rats [33]. A
high concentration of cholesterol in human serum is one of
the primary factors in the development of atherosclerosis [34].
Themarkedhyperlipidemiathatcharacterizesthediabeticstate
may therefore be regarded as a consequence of the uninhibited
actions of lipolytic hormones on the fat depot [35].
The antihyperlipidemic effect of GLEt may be due to the
down-regulation of NADPH and NADH, cofactors in the fat
metabolism. Higher activity of glucose-6-posphatase provides
H+ thatbindswithNADP+ toformofNADPHandishelpfulin
thesynthesisoffatsfromcarbohydrates.Whenglycolysisslows
down because of cellular activity, the pentose phosphate path-
way still remains active in liver to breakdown glucose, which
continuously provides NADPH. Enhanced hexokinase activity
in GLEt-treated rats suggests greater uptake of glucose from
blood by the liver cells.
Activitiesofenzymesuggestthatenhancedlipidmetabolism
during diabetes is shifted toward carbohydrate metabolism and
itenhancestheutilizationofglucoseattheperipheralsites.One
of the possible actions of GLEt may be due to its inhibition on
endogenous synthesis of lipids.
Alteration of fatty acid composition by increased lipid lev-
els contribute to lowering the resistance of tissues and higher
rate of oxidative stress. Our results show increased lipid per-
oxidation markers TBARS and hydroperoxides contributing to
oxidative stress. Decreased activity of glucose-6-phosphatase
through pentose phosphate shunt results in a high reduced glu-
tathionetooxidizedglutathioneratio(GSH/GSSG)[32],which
is coupled with the conversion of NADPH to NADP. Admin-
istration of GLEt to diabetic rats decreased lipid peroxidation
and increased the glutathione content. GLEt may produce high
levels of NADP+, which result in down-regulation of lipogen-
esis and lower risk of the tissues for oxidative stress and higher
resistance for diabetes.
The overwhelming evidence demonstrated above indicates
that hyperglycemia coupled with hyperlipidemia increases the
risk for cardiovascular diseases. GLEt signiﬁcantly reduces the
levels of serum and tissue lipids, which are actively raised in
alloxan diabetic rats. GLEt has beneﬁcial effect on plasma in-
sulin and hexokinase activity. These ﬁndings strengthen the
observation that naturally occurring compounds of plant origin
have antidiabetic effects.ANTIHYPERLIPIDEMIC EFFECT OF GYMNEMA MONTANUM 189
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